A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

Trial Profile

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs CX 2009 (Primary)
  • Indications Breast cancer; Cholangiocarcinoma; Endometrial cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms PROCLAIM-CX-2009
  • Sponsors CytomX Therapeutics
  • Most Recent Events

    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 08 Sep 2017 According to a CytomX Therapeutics media release, trial design will be presented at at the European Society for Medical Oncology Annual Meeting.
    • 28 Jun 2017 According to a CytomX Therapeutics media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top